Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2015, LYZZ Capital is a global venture capital and private equity firm headquartered in Shanghai, with an additional office in San Diego. The firm manages over USD $600 million across both USD and RMB investments, focusing primarily on the healthcare sector. LYZZ Capital has over 20 years of experience in biotech investments and has established a strong presence in China, where it has been active for more than 15 years.
The firm’s team consists of seasoned investment and operating professionals who have backgrounds in leading pharmaceutical and biotech companies, as well as Wall Street firms. This diverse expertise allows LYZZ Capital to implement cross-border strategies that facilitate the entry of global biotech and medtech assets into China and vice versa. The firm emphasizes investments that address unmet medical needs and have significant market potential, particularly in the Asian market.
LYZZ Capital primarily invests in the healthcare sector, with a strong emphasis on biotech companies. The firm targets investments that address unmet medical needs and possess substantial market potential, particularly in China. LYZZ Capital's investment strategy includes sectors such as medical devices, drug discovery, and digital health, employing a value investing approach that leverages business judgment and market foresight.
The firm seeks to identify talents, assets, and technologies that can significantly impact healthcare outcomes. LYZZ Capital's cross-border investment thesis differentiates it from other firms, as it focuses on bringing Western biotech and medtech innovations to the Chinese market while also promoting Chinese innovations globally. This dual approach allows LYZZ Capital to capitalize on the growing demand for healthcare solutions in China and beyond.
LYZZ Capital has a diverse portfolio of 38 companies, primarily focused on healthcare and biotech. Notable portfolio companies include:
Among its notable exits, LYZZ Capital achieved a significant milestone with the IPO of Microtech Medical, which listed on the HKEX in October 2021 with a market capitalization of approximately $1.7 billion.
Kevin Li (李凯军) - Co-Founder & Managing Partner. Kevin has over 20 years of experience in biomed and biotech investing. He previously served as a Partner at DT Capital and HBM BioMed China, and was an Associate at Toucan Capital in the US. He is also the Chairman at Mojia Biotech.
Jason Zhu - Co-Founder & Managing Partner. Jason brings extensive experience in the healthcare investment space, contributing to LYZZ Capital's strategic direction and investment decisions.
The team at LYZZ Capital comprises investment and operating professionals from major pharmaceutical and biotech firms, as well as Wall Street, providing a strong foundation for supporting portfolio companies in navigating complex market dynamics.
To pitch LYZZ Capital, founders should send their proposals via email to ir@lyzzcap.com. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. Founders should expect a response within a few weeks, depending on the volume of inquiries.
Warm introductions are preferred, as they can facilitate a more favorable review of the pitch. LYZZ Capital appreciates detailed presentations that highlight how the startup aligns with their investment thesis focused on unmet medical needs in the healthcare sector.
In recent months, LYZZ Capital has been actively expanding its portfolio, focusing on investments that meet critical healthcare demands, particularly in the Chinese market. The firm continues to reinforce its commitment to healthcare innovation by identifying and supporting companies that address unmet medical needs.
Notably, LYZZ Capital celebrated the successful IPO of Microtech Medical on the HKEX in October 2021, achieving a market capitalization of approximately $1.7 billion. This exit highlights the firm's ability to identify and nurture high-potential healthcare companies.
What are LYZZ Capital's investment criteria?
LYZZ Capital focuses on investments in the healthcare sector, particularly in biotech companies that address unmet medical needs and have substantial market potential, especially in China. The firm looks for innovative solutions in medical devices, drug discovery, and digital health.
How can I pitch to LYZZ Capital?
Founders can reach out to LYZZ Capital via email at ir@lyzzcap.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and team background.
What makes LYZZ Capital different from other investors?
LYZZ Capital differentiates itself through its cross-border investment strategy, which focuses on bringing global biotech and medtech innovations into China while promoting Chinese innovations to international markets. The firm leverages its extensive network and industry expertise to support portfolio companies.
What is the geographic scope of LYZZ Capital's investments?
LYZZ Capital invests globally, with a strong focus on the Chinese market. The firm has a significant operational presence in both China and the United States, allowing it to navigate complex market dynamics effectively.
What is the typical check size for investments?
While specific check sizes are not disclosed, LYZZ Capital typically invests in rounds that align with its strategy of supporting companies addressing critical healthcare needs. The firm manages over $600 million in total assets under management, indicating a capacity for substantial investments.
What kind of support does LYZZ Capital provide to its portfolio companies?
LYZZ Capital adds value through its extensive network in the healthcare sector, deep industry expertise, and a cross-border strategy that facilitates access to both Chinese and global markets. The firm’s team provides operational support and strategic guidance to help portfolio companies navigate market challenges.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.